eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Shire Pharmaceuticals Limited
Hampshire International Business Park, Chineham, Basingstoke, Hampshire , RG24 8EP
Telephone: +44 (0)1256 894 000
WWW: http://www.shire.com
Medical Information Direct Line: 0800 055 6614
Medical Information e-mail: medinfoUK@shire.com
Customer Care direct line: +44 (0)1256 894 107

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 01/09/2010
SPC Calcichew 500mg Chewable Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 01/09/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   09-Jun-2010
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Addition of posology information relating to hepatic and renal challenged patients; reinstatement of interactions with levothyroxine and the introduction of interactions with quinolones; reinstatement of side effects for milk alkali syndrome and addition of dyspepsia. 
Updated on 26/08/2009 and displayed until 01/09/2010
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   18-Jul-2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
In section 10 Correction of the approval date from 17-Jul-2007 to 18-Jul-2007.
Updated on 31/07/2007 and displayed until 26/08/2009
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 6.1 - List of Excipients
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   07/2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Change to Section 4.4 Warnings and 6.1 Excipient presentation
Updated on 05/07/2007 and displayed until 31/07/2007
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 28/06/2007 and displayed until 05/07/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 4 - Special Precautions for Storage
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   04/2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
update to posology of "suck or chew"; updates to names of excipients, removal of 'to protect from moisture', other typing corrections.
Updated on 16/03/2007 and displayed until 28/06/2007
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   02/2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Update Section 4.9 Overdose in line with MHRA guidelines on gastric lavage
Updated on 15/03/2007 and displayed until 16/03/2007
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   02/2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Update to Section 4.9 Overdose in line with MHRA guidelines on Gastric Lavage
Updated on 26/05/2004 and displayed until 15/03/2007
Reasons for adding or updating:
  • Change to section 1 - trade name
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 3 - pharmaceutical form
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.3 - Contra-indications
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6.1 - List of Excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 6 - Instruction for Use/Handling
  • Change to section 10 (date of (partial) revision of the text
Updated on 19/03/2002 and displayed until 26/05/2004
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 4 - Special Precautions for Storage
Updated on 12/07/2001 and displayed until 19/03/2002
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
Updated on 06/09/1999 and displayed until 12/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  calcium carbonate